Your shopping cart is currently empty

Prostratin (12-Deoxyphorbol-13-acetate) is an orally active protein kinase C (PKC) activator with a Ki value of 12.5 nM.As an NF-κB activator, Prostratin activates HIV gene expression in T cells.Prostratin inhibits the growth of acute myeloid leukemia (AML) cell lines and enhances cytarabine-induced AML cell differentiation. In addition, Prostratin induced KRAS phosphorylation and inhibited the growth of KRAS-mutated tumors.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 500 μg | $154 | 35 days | 35 days | |
| 1 mg | $211 | 35 days | 35 days |
| Description | Prostratin (12-Deoxyphorbol-13-acetate) is an orally active protein kinase C (PKC) activator with a Ki value of 12.5 nM.As an NF-κB activator, Prostratin activates HIV gene expression in T cells.Prostratin inhibits the growth of acute myeloid leukemia (AML) cell lines and enhances cytarabine-induced AML cell differentiation. In addition, Prostratin induced KRAS phosphorylation and inhibited the growth of KRAS-mutated tumors. |
| Targets&IC50 | PKC:12.5 nM (Ki) |
| In vitro | Methods: Prostratin (125, 250, 500, 1000 nM) was used to treat HL-60, NB4, and U937 cells to evaluate its effect on leukemia cell growth. Results: Prostratin showed similar concentration- and time-dependent growth inhibition on all three cell lines. [2] |
| Synonyms | 12-Deoxyphorbol-13-acetate |
| Molecular Weight | 390.47 |
| Formula | C22H30O6 |
| Cas No. | 60857-08-1 |
| Smiles | O(C(C)=O)[C@@]12[C@@](C1(C)C)([C@]3([C@](O)([C@H](C)C2)[C@]4([C@](O)(CC(CO)=C3)C(=O)C(C)=C4)[H])[H])[H] |
| Relative Density. | 1.31 g/cm3 |
| Storage | store at low temperature | store at 4°C | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 40 mg/mL (102.44 mM), Sonication is recommended. H2O: < 1 mg/mL (insoluble) | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 1.5 mg/mL (3.84 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.